Karampoor Sajad, Zahednasab Hamid, Ramagopalan Sreeram, Mehrpour Masoud, Safarnejad Tameshkel Fahimeh, Keyvani Hossein
Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
J Neuroimmunol. 2016 Jan 15;290:47-8. doi: 10.1016/j.jneuroim.2015.11.017. Epub 2015 Nov 29.
Vitamin D is being increasingly studied in multiple sclerosis (MS). A number of studies have shown that MS patients have lower levels of 25-hydroxyvitamin D as compared to comparator populations, but previous studies in Iran have been conflicting, perhaps due to their small sample size. We performed the largest study to date investigating 25-hydroxyvitamin D levels in Iranian MS patients (n=700) and controls (n=1000). 25-hydroxyvitamin D was measured using a quantitative chemiluminescent immunometric assay. 25-hydroxyvitamin D levels were lower in patients with MS. Over 24% of controls were vitamin D sufficient as compared to 3.4% of patients. Logistic regression showed that for every 1 ng/mL increase in 25-hydroxyvitamin D, the odds for MS decreased (odds ratio=0.87; 95% confidence interval (CI) 0.85-0.88; p<0.001), after adjusting for age and sex. There was no association between 25-hydroxyvitamin D levels and disability scores in MS patients. Iranian Patients with MS have low levels of vitamin D and, where deemed necessary, appropriate supplementation should be given.
维生素D在多发性硬化症（MS）中的研究日益增多。多项研究表明，与对照人群相比，MS患者的25-羟基维生素D水平较低，但伊朗此前的研究结果相互矛盾，可能是由于样本量较小。我们开展了迄今为止规模最大的一项研究，调查伊朗MS患者（n = 700）和对照组（n = 1000）的25-羟基维生素D水平。采用定量化学发光免疫分析法测定25-羟基维生素D。MS患者的25-羟基维生素D水平较低。超过24%的对照组维生素D充足，而患者组这一比例为3.4%。逻辑回归分析显示，在调整年龄和性别后，25-羟基维生素D每增加1 ng/mL，MS的患病几率就会降低（优势比=0.87；95%置信区间（CI）0.85 - 0.88；p<0.001）。MS患者的25-羟基维生素D水平与残疾评分之间无关联。伊朗MS患者的维生素D水平较低，在必要时应给予适当补充。
